Related Experiment Video
Updated: Jun 26, 2025
Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures
Published on: December 26, 2016
Fresh Insights Into SLC25A26: Potential New Therapeutic Target for Cancers: A Review
Yangheng Xu1, Zhisheng Hong2, Sheng Yu1
1Science and Engineering, National University of Defense Technology, Changsha, China.
Abstract:
SLC25A26 is the only known human mitochondrial S-adenosylmethionine carrier encoding gene. Recent studies have shown that SLC25A26 is abnormally expressed in some cancers, such as cervical cancer, low-grade glioma, non-small cell lung cancer, and liver cancer, which suggests SLC25A26 can affect the occurrence and development of some cancers. This article in brief briefly reviewed mitochondrial S-adenosylmethionine carrier in different species and its encoding gene, focused on the association of SLC25A26 aberrant expression and some cancers as well as potential mechanisms, summarized its potential for cancer prognosis, and characteristics of mitochondrial diseases caused by SLC25A26 mutation. Finally, we provide a brief expectation that needs to be further investigated. We speculate that SLC25A26 will be a potential new therapeutic target for some cancers.
Insights
The SLC25A26 gene, encoding the mitochondrial S-adenosylmethionine carrier, shows abnormal expression in various cancers. This suggests SLC25A26 may be a potential therapeutic target for cancer treatment.
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- SLC25A26 is the sole human gene encoding the mitochondrial S-adenosylmethionine carrier.
- Aberrant SLC25A26 expression is observed in cervical, glioma, lung, and liver cancers.
- This suggests a role for SLC25A26 in cancer development.
Purpose of the Study:
- To review the mitochondrial S-adenosylmethionine carrier and its gene across species.
- To focus on the association between SLC25A26 aberrant expression and cancer.
- To summarize potential mechanisms, prognostic value, and mitochondrial disease links.
Main Methods:
- Literature review of existing studies on SLC25A26.
- Analysis of the association between SLC25A26 expression and various cancers.
- Summary of potential mechanisms and clinical implications.
Main Results:
- SLC25A26 expression is altered in several cancer types, including cervical, glioma, non-small cell lung, and liver cancers.
- Abnormal SLC25A26 expression is linked to cancer occurrence and progression.
- SLC25A26 mutations are associated with mitochondrial diseases.
Conclusions:
- SLC25A26 plays a significant role in the development of certain cancers.
- SLC25A26 holds potential as a prognostic marker for cancer.
- SLC25A26 represents a promising novel therapeutic target for oncological diseases.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...